BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/28/2020 8:26:09 AM | Browse: 799 | Download: 1758
 |
Received |
|
2020-07-31 04:13 |
|
Peer-Review Started |
|
2020-07-31 04:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-08-22 18:26 |
|
Revised |
|
2020-08-28 06:22 |
|
Second Decision |
|
2020-09-16 12:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-17 04:50 |
|
Articles in Press |
|
2020-09-17 04:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-27 01:43 |
|
Publish the Manuscript Online |
|
2020-10-28 08:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Lakmie S Gunarathne, Harinda Rajapaksha, Nicholas Shackel, Peter W Angus and Chandana B Herath |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Health and Medical Research Council (NHMRC) of Australia Project Grants |
APP1124125 |
|
| Corresponding Author |
Chandana B Herath, PhD, Senior Lecturer, South Western Sydney Clinical School, Faculty of Medicine, University of New South Wales, Ingham Institute for Applied Medical Research, 1 Campbell Street, Liverpool 2170, NSW, Australia. c.herath@unsw.edu.au |
| Key Words |
Portal hypertension; Cirrhosis; Intrahepatic vascular resistance; Hyperdynamic circulatory state; Splanchnic vasodilatation; Portal blood flow |
| Core Tip |
Cirrhosis is a major cause of death and affects over 300 million people worldwide. Portal hypertension is a life-threatening complication of cirrhosis, characterized by splanchnic vasodilatation, the formation of varices and variceal bleeding, which account for much of the mortality and morbidity in cirrhotic patients. Current ‘gold standard’ clinical treatment is non-selective b-blockers; however, their efficacy and tolerability are suboptimal. Recent findings from the author’s laboratory and others suggest that the alternate renin angiotensin system is a potential target to design and develop novel therapeutics to inhibit splanchnic vasodilatation in cirrhotic portal hypertension. |
| Publish Date |
2020-10-28 08:26 |
| Citation |
Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020; 26(40): 6111-6140 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i40/6111.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i40.6111 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
